柑橘黄酮片的质量控制及药动学研究概述
Overview of Quality Control and Pharmaco-Kinetic of Citrus Bioflavonoids Tablets
摘要: 柑橘黄酮片为复方制剂，主要成分为地奥司明和橙皮苷，临床上常用于治疗静脉淋巴功能不全和急性痔疮发作等相关病症。此外，该药物还具抗炎、抗氧化、抗肿瘤等多种药理活性，应用前景良好。本文从药物的制备、质量控制及药动学等方面的研究进展进行概述，以期为该药物的进一步开发研究提供参考。
Abstract: Citrus bioflavonoids tablet is a compound preparation, the main components are diosmin and hesperidin. It is commonly used to treat venous lymphatic insufficiency and acute hemorrhoid attacks and other related diseases in clinic. In addition, the drug also has anti-inflammatory, antioxidant, anti-tumor and other pharmacological activities, and has a good application prospect. This paper summarizes the research progress of drug preparation, quality control and pharmacokinetics, in order to provide reference for further development of the drug.
文章引用：林雯, 夏玉凤. 柑橘黄酮片的质量控制及药动学研究概述[J]. 药物资讯, 2022, 11(2): 59-65. https://doi.org/10.12677/PI.2022.112008

参考文献

[1] Nicolaides, A., Kakkos, S., Baekgaard, N., et al. (2018) Management of Chronic Venous Disorders of the Lower Limbs. Guidelines According to Scientific Evidence. Part I. International Angiology, 37, 181-254. [Google Scholar] [CrossRef] 
[2] 中国中西医结合学会大肠肛门病专业委员会. 中国痔病诊疗指南(2020) [J]. 结直肠肛门外科, 2020, 26(5): 519-533.
[3] 李玉山. 地奥司明药理作用及临床应用研究进展[J]. 海峡药学, 2015, 27(12): 81-85.
[4] Zheng, Y., Zhang, R., Shi, W., et al. (2020) Metabolism and Pharmacolog-ical Activities of the Natural Health-Benefiting Compound Diosmin. Food & Function, 11, 8472-8492. [Google Scholar] [CrossRef] 
[5] Li, C. and Schluesener, H. (2017) Health-Promoting Effects of the Cit-rus Flavanone Hesperidin. Critical Reviews in Food Science and Nutrition, 57, 613-631. [Google Scholar] [CrossRef] [PubMed]
[6] Garner, R.C., Garner, J.V., Gregory, S., et al. (2002) Com-parison of the Absorption of Micronized (Daflon 500 mg) and Nonmicronized 14C-Diosmin Tablets after Oral Admin-istration to Healthy Volunteers by Accelerator Mass Spectrometry and Liquid Scintillation Counting. Journal of Phar-maceutical Sciences, 91, 32-40. [Google Scholar] [CrossRef] [PubMed]
[7] Adouani, I., Qureshi, A.S. and Hang, T.J. (2020) Preparation, Evaluation and Pharmacokinetics of Diosmin Herbosome in Beagle Dogs. Pakistan Journal of Pharmaceutical Sciences, 33, 33-40.
[8] 王陈翔, 黄爱芳, 金辉, 等. 地奥司明栓剂的制备及质量控制研究[J]. 药学实践杂志, 2017, 35(4): 325-327+349.
[9] Tajana, A., Boccasanta, P., Micheletto, G., et al. (1988) Results of the Use of Topical Diosmin (Venosmine) in the Treatment of Acute Hemorrhoid Pathology. Minerva Medica, 79, 387-390.
[10] Allaert, F.A. (2012) Meta-Analysis of the Impact of the Principal Venoactive Drugs Agents on Malleolar Venous Edema. International Angi-ology, 31, 310-315.
[11] Paysant, J., Sansilvestrimorel, P., Bouskela, E., et al.(2008) Different Flavonoids Present in the Micronized Purified Flavonoid Fraction (Daflon 500 mg) Contribute to Its Anti-Hyperpermeability Effect in the Hamster Cheek Pouch Microcirculation. International Angiology: A Journal of the International Union of Angiology, 27, 81.
[12] Cazaubon, M., Benigni, J.P., Steinbruch, M., et al. (2021) Is There a Difference in the Clinical Efficacy of Di-osmin and Micronized Purified Flavonoid Fraction for the Treatment of Chronic Venous Disorders? Review of Available Evidence. Vascular Health and Risk Management, 17, 591-600. [Google Scholar] [CrossRef] 
[13] Meyer, O.C. (1994) Safety and Security of Daflon 500 mg in Ve-nous Insufficiency and in Hemorrhoidal Disease. Angiology, 45, 579-584. [Google Scholar] [CrossRef] [PubMed]
[14] Bogucka-Kocka, A., Woźniak, M., Feldo, M., et al. (2013) Di-osmin—Isolation Techniques, Determination in Plant Material and Pharmaceutical Formulations, and Clinical Use. Natu-ral Product Communications, 8, 545-550. [Google Scholar] [CrossRef] 
[15] Murota, K., Nakamura, Y. and Uehara, M. (2018) Flavonoid Metabolism: The Interaction of Metabolites and Gut Microbiota. Bioscience, Biotechnology, and Biochemistry, 82, 600-610. [Google Scholar] [CrossRef] [PubMed]
[16] 曾晓丽, 谢燕, 袁秀荣. 黄酮类化合物体内过程的研究进展[J]. 中国新药杂志, 2010, 19(9): 750-754.
[17] Gerges, S.H., Wahdan, S.A., Elsherbiny, D.A., et al. (2021) Pharmacology of Diosmin, a Citrus Flavone Glycoside: An Updated Review. European Journal of Drug Metab-olism and Pharmacokinetics, 47, 1-18. [Google Scholar] [CrossRef] [PubMed]
[18] Talibov, O.B. (2019) Diosmin in the Treatment of Venous Dis-ease: Pharmacokinetics and Pharmacodynamics (In Russian Only]. Khirurgiia (Mosk), 135-140. [Google Scholar] [CrossRef] [PubMed]
[19] Silvestro, L., Tarcomnicu, I., Dulea, C., et al. (2013) Confirma-tion of Diosmetin 3-O-Glucuronide as Major Metabolite of Diosmin in Humans, Using Mi-cro-Liquid-Chromatography-Mass Spectrometry and Ion Mobility Mass Spectrometry. Analytical and Bioanalytical Chemistry, 405, 8295-8310. [Google Scholar] [CrossRef] [PubMed]
[20] Manach, C., Morand, C., Gil-Izquierdo, A., et al. (2003) Bioavailability in Humans of the Flavanones Hesperidin and Narirutin after the Ingestion of Two Doses of Orange Juice. European Journal of Clinical Nutrition, 57, 235-242. [Google Scholar] [CrossRef] [PubMed]
[21] Matsumoto, H., Ikoma, Y., Sugiura, M., et al. (2004) Identification and Quantification of the Conjugated Metabolites Derived from Orally Administered Hesperidin in Rat Plasma. Journal of Agricultural and Food Chemistry, 52, 6653-6659. [Google Scholar] [CrossRef] [PubMed]
[22] Nectoux, A.M., Abe, C., Huang, S.W., et al. (2019) Absorption and Meta-bolic Behavior of Hesperidin (Rutinosylated Hesperetin) after Single Oral Administration to Sprague-Dawley Rats. Journal of Agricultural and Food Chemistry, 67, 9812-9819. [Google Scholar] [CrossRef] [PubMed]
[23] Spanakis, M., Kasmas, S. and Niopas, I. (2009) Simultaneous De-termination of the Flavonoid Aglycones Diosmetin and Hesperetin in Human Plasma and Urine by a Validated GC/MS Method: In Vivo Metabolic Reduction of Diosmetin to Hesperetin. Biomedical Chromatography, 23, 124-131. [Google Scholar] [CrossRef] [PubMed]
[24] Mandal, P., Dan, S., Chakraborty, S., et al. (2019) Simultaneous Determina-tion and Quantitation of Diosmetin and Hesperetin in Human Plasma by Liquid Chromatographic Mass Spectrometry with an Application to Pharmacokinetic Studies. Journal of Chromatographic Science, 57, 451-461. [Google Scholar] [CrossRef] [PubMed]
[25] 朱婷婷, 杜明荦, 苏浩明, 等. 地奥司明片在健康人体内的药动学[J]. 中国新药杂志, 2014, 23(14): 1674-1678.
[26] Bedada, S.K. and Neerati, P. (2018) Modulation of CYP3A En-zyme Activity by Diosmin and Its Consequence on Carbamazepine Pharmacokinetics in Rats. Naunyn-Schmiedeberg’s Archives of Pharmacology, 391, 115-121. [Google Scholar] [CrossRef] [PubMed]
[27] Bedada, S.K. and Boga, P.K. (2017) Influence of Diosmin on the Metabolism and Disposition of Carbamazepine in Healthy Subjects. Xenobiotica, 47, 879-884. [Google Scholar] [CrossRef] [PubMed]
[28] Rajnarayana, K., Venkatesham, A., Nagulu, M., et al. (2008) Influence of Diosmin Pretreatment on the Pharmacokinetics of Chlorzoxazone in Healthy Male Volunteers. Drug Metab-olism and Drug Interactions, 23, 311-321. [Google Scholar] [CrossRef] 
[29] Rajnarayana, K., Venkatesham, A. and Krishna, D.R. (2007) Bioavailability of Diclofenac Sodium after Pretreatment with Diosmin in Healthy Volunteers. Drug Metabolism and Drug Interactions, 22, 165-174. [Google Scholar] [CrossRef] 
[30] Bedada, S.K., Boga, P.K. and Kotakonda, H.K. (2017) The Effect of Diosmin on the Pharmacokinetics of Fexofenadine in Healthy Human Volunteers. Xenobiotica, 47, 230-235. [Google Scholar] [CrossRef] [PubMed]
[31] Neerati, P. and Bedada, S.K. (2015) Effect of Diosmin on the Intestinal Absorption and Pharmacokinetics of Fexofenadine in Rats. Pharmacological Reports, 67, 339-344. [Google Scholar] [CrossRef] [PubMed]
[32] Amato, C. (1994) Advantage of a Micronized Flavonoidic Frac-tion (Daflon 500 mg) in Comparison with a Nonmicronizeddiosmin. Angiology, 45, 531-536.
[33] 于航, 郑瑞芳, 苏文灵, 等. 基于肠道菌的黄酮类成分代谢特征及药理学思考[J]. 药学学报, 2021, 56(7): 1757-1768+1748.